A citation-based method for searching scientific literature

Philip J Mease, Apinya Lertratanakul, Jaclyn K Anderson, Kim Papp, Filip Van den Bosch, Shigeyoshi Tsuji, Eva Dokoupilova, Mauro Keiserman, Xin Wang, Sheng Zhong, Reva M McCaskill, Patrick Zueger, Aileen L Pangan, William Tillett. Ann Rheum Dis 2021
Times Cited: 56







List of co-cited articles
523 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis.
Iain B McInnes, Jaclyn K Anderson, Marina Magrey, Joseph F Merola, Yi Liu, Mitsumasa Kishimoto, Slawomir Jeka, Cesar Pacheco-Tena, Xin Wang, Liang Chen,[...]. N Engl J Med 2021
51
60

Tofacitinib or Adalimumab versus Placebo for Psoriatic Arthritis.
Philip Mease, Stephen Hall, Oliver FitzGerald, Désirée van der Heijde, Joseph F Merola, Francisco Avila-Zapata, Dorota Cieślak, Daniela Graham, Cunshan Wang, Sujatha Menon,[...]. N Engl J Med 2017
268
41

Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.
Désirée van der Heijde, In-Ho Song, Aileen L Pangan, Atul Deodhar, Filip van den Bosch, Walter P Maksymowych, Tae-Hwan Kim, Mitsumasa Kishimoto, Andrea Everding, Yunxia Sui,[...]. Lancet 2019
111
39

Tofacitinib for Psoriatic Arthritis in Patients with an Inadequate Response to TNF Inhibitors.
Dafna Gladman, William Rigby, Valderilio F Azevedo, Frank Behrens, Ricardo Blanco, Andrzej Kaszuba, Elizabeth Kudlacz, Cunshan Wang, Sujatha Menon, Thijs Hendrikx,[...]. N Engl J Med 2017
253
39

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update.
Laure Gossec, Xenofon Baraliakos, Andreas Kerschbaumer, Maarten de Wit, Iain McInnes, Maxime Dougados, Jette Primdahl, Dennis G McGonagle, Daniel Aletaha, Andra Balanescu,[...]. Ann Rheum Dis 2020
295
35

In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494).
Julie M Parmentier, Jeff Voss, Candace Graff, Annette Schwartz, Maria Argiriadi, Michael Friedman, Heidi S Camp, Robert J Padley, Jonathan S George, Deborah Hyland,[...]. BMC Rheumatol 2018
135
28

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active psoriatic arthritis (EQUATOR): results from a randomised, placebo-controlled, phase 2 trial.
Philip Mease, Laura C Coates, Philip S Helliwell, Mykola Stanislavchuk, Anna Rychlewska-Hanczewska, Anna Dudek, Walid Abi-Saab, Chantal Tasset, Luc Meuleners, Pille Harrison,[...]. Lancet 2018
102
28

Efficacy and safety of filgotinib, a selective Janus kinase 1 inhibitor, in patients with active ankylosing spondylitis (TORTUGA): results from a randomised, placebo-controlled, phase 2 trial.
Désirée van der Heijde, Xenofon Baraliakos, Lianne S Gensler, Walter P Maksymowych, Vira Tseluyko, Oleg Nadashkevich, Walid Abi-Saab, Chantal Tasset, Luc Meuleners, Robin Besuyen,[...]. Lancet 2018
132
26

Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
Roy Fleischmann, Aileen L Pangan, In-Ho Song, Eduardo Mysler, Louis Bessette, Charles Peterfy, Patrick Durez, Andrew J Ostor, Yihan Li, Yijie Zhou,[...]. Arthritis Rheumatol 2019
169
26

Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the SELECT phase III clinical programme.
Stanley B Cohen, Ronald F van Vollenhoven, Kevin L Winthrop, Cristiano A F Zerbini, Yoshiya Tanaka, Louis Bessette, Ying Zhang, Nasser Khan, Barbara Hendrickson, Jeffrey V Enejosa,[...]. Ann Rheum Dis 2021
62
25

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.
Josef S Smolen, Aileen L Pangan, Paul Emery, William Rigby, Yoshiya Tanaka, Juan Ignacio Vargas, Ying Zhang, Nemanja Damjanov, Alan Friedman, Ahmed A Othman,[...]. Lancet 2019
144
25

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.
Laura C Coates, Arthur Kavanaugh, Philip J Mease, Enrique R Soriano, Maria Laura Acosta-Felquer, April W Armstrong, Wilson Bautista-Molano, Wolf-Henning Boehncke, Willemina Campbell, Alberto Cauli,[...]. Arthritis Rheumatol 2016
533
23

Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Mark C Genovese, Roy Fleischmann, Bernard Combe, Stephen Hall, Andrea Rubbert-Roth, Ying Zhang, Yijie Zhou, Mohamed-Eslam F Mohamed, Sebastian Meerwein, Aileen L Pangan. Lancet 2018
204
21

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial.
Philip J Mease, Proton Rahman, Alice B Gottlieb, Alexa P Kollmeier, Elizabeth C Hsia, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou, Yanli Zhuang,[...]. Lancet 2020
106
21

Psoriatic Arthritis.
Christopher T Ritchlin, Robert A Colbert, Dafna D Gladman. N Engl J Med 2017
603
19

Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study.
Désirée van der Heijde, Atul Deodhar, James C Wei, Edit Drescher, Dona Fleishaker, Thijs Hendrikx, David Li, Sujatha Menon, Keith S Kanik. Ann Rheum Dis 2017
194
19

Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial.
Atul Deodhar, Philip S Helliwell, Wolf-Henning Boehncke, Alexa P Kollmeier, Elizabeth C Hsia, Ramanand A Subramanian, Xie L Xu, Shihong Sheng, Prasheen Agarwal, Bei Zhou,[...]. Lancet 2020
108
19

Safety and efficacy of upadacitinib in patients with rheumatoid arthritis and inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (SELECT-NEXT): a randomised, double-blind, placebo-controlled phase 3 trial.
Gerd R Burmester, Joel M Kremer, Filip Van den Bosch, Alan Kivitz, Louis Bessette, Yihan Li, Yijie Zhou, Ahmed A Othman, Aileen L Pangan, Heidi S Camp. Lancet 2018
180
17

Efficacy and Safety of Upadacitinib Monotherapy in Methotrexate-Naive Patients With Moderately-to-Severely Active Rheumatoid Arthritis (SELECT-EARLY): A Multicenter, Multi-Country, Randomized, Double-Blind, Active Comparator-Controlled Trial.
Ronald van Vollenhoven, Tsutomu Takeuchi, Aileen L Pangan, Alan Friedman, Mohamed-Eslam F Mohamed, Su Chen, Maureen Rischmueller, Ricardo Blanco, Ricardo M Xavier, Vibeke Strand. Arthritis Rheumatol 2020
71
17

JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.
Shubhasree Banerjee, Ann Biehl, Massimo Gadina, Sarfaraz Hasni, Daniella M Schwartz. Drugs 2017
407
16


Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.
Jasvinder A Singh, Gordon Guyatt, Alexis Ogdie, Dafna D Gladman, Chad Deal, Atul Deodhar, Maureen Dubreuil, Jonathan Dunham, M Elaine Husni, Sarah Kenny,[...]. Arthritis Rheumatol 2019
185
16

Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials.
Julian Panés, William J Sandborn, Stefan Schreiber, Bruce E Sands, Séverine Vermeire, Geert D'Haens, Remo Panaccione, Peter D R Higgins, Jean-Frederic Colombel, Brian G Feagan,[...]. Gut 2017
201
14

Safety Profile of Baricitinib in Patients with Active Rheumatoid Arthritis with over 2 Years Median Time in Treatment.
Josef S Smolen, Mark C Genovese, Tsutomu Takeuchi, David L Hyslop, William L Macias, Terence Rooney, Lei Chen, Christina L Dickson, Jennifer Riddle Camp, Tracy E Cardillo,[...]. J Rheumatol 2019
143
14

Special Article: 2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis.
Jasvinder A Singh, Gordon Guyatt, Alexis Ogdie, Dafna D Gladman, Chad Deal, Atul Deodhar, Maureen Dubreuil, Jonathan Dunham, M Elaine Husni, Sarah Kenny,[...]. Arthritis Care Res (Hoboken) 2019
130
14

Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis.
William J Sandborn, Subrata Ghosh, Julian Panes, Stefan Schreiber, Geert D'Haens, Satoshi Tanida, Jesse Siffledeen, Jeffrey Enejosa, Wen Zhou, Ahmed A Othman,[...]. Gastroenterology 2020
84
14

Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease.
William J Sandborn, Brian G Feagan, Edward V Loftus, Laurent Peyrin-Biroulet, Gert Van Assche, Geert D'Haens, Stefan Schreiber, Jean-Frederic Colombel, James D Lewis, Subrata Ghosh,[...]. Gastroenterology 2020
84
14

Phase 2 Trial of Selective Tyrosine Kinase 2 Inhibition in Psoriasis.
Kim Papp, Kenneth Gordon, Diamant Thaçi, Akimichi Morita, Melinda Gooderham, Peter Foley, Ihab G Girgis, Sudeep Kundu, Subhashis Banerjee. N Engl J Med 2018
175
14

Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study.
Atul Deodhar, Paula Sliwinska-Stanczyk, Huji Xu, Xenofon Baraliakos, Lianne S Gensler, Dona Fleishaker, Lisy Wang, Joseph Wu, Sujatha Menon, Cunshan Wang,[...]. Ann Rheum Dis 2021
37
21

Trial of Upadacitinib or Abatacept in Rheumatoid Arthritis.
Andrea Rubbert-Roth, Jeffrey Enejosa, Aileen L Pangan, Boulos Haraoui, Maureen Rischmueller, Nasser Khan, Ying Zhang, Naomi Martin, Ricardo M Xavier. N Engl J Med 2020
67
14

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.
Josef S Smolen, Monika Schöls, Jürgen Braun, Maxime Dougados, Oliver FitzGerald, Dafna D Gladman, Arthur Kavanaugh, Robert Landewé, Philip Mease, Joachim Sieper,[...]. Ann Rheum Dis 2018
327
12

Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations.
Iain B McInnes, Nicole L Byers, Richard E Higgs, Jonathan Lee, William L Macias, Songqing Na, Robert A Ortmann, Guilherme Rocha, Terence P Rooney, Thomas Wehrman,[...]. Arthritis Res Ther 2019
98
12

Effect of Filgotinib vs Placebo on Clinical Response in Patients With Moderate to Severe Rheumatoid Arthritis Refractory to Disease-Modifying Antirheumatic Drug Therapy: The FINCH 2 Randomized Clinical Trial.
Mark C Genovese, Kenneth Kalunian, Jacques-Eric Gottenberg, Neelufar Mozaffarian, Beatrix Bartok, Franziska Matzkies, Jie Gao, Ying Guo, Chantal Tasset, John S Sundy,[...]. JAMA 2019
135
12

Incidence of venous and arterial thromboembolic events reported in the tofacitinib rheumatoid arthritis, psoriasis and psoriatic arthritis development programmes and from real-world data.
Philip Mease, Christina Charles-Schoeman, Stanley Cohen, Lara Fallon, John Woolcott, Huifeng Yun, Joel Kremer, Jeffrey Greenberg, Wendi Malley, Alina Onofrei,[...]. Ann Rheum Dis 2020
78
12

Classification criteria for psoriatic arthritis: development of new criteria from a large international study.
William Taylor, Dafna Gladman, Philip Helliwell, Antonio Marchesoni, Philip Mease, Herman Mielants. Arthritis Rheum 2006
12

Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial.
Emma Guttman-Yassky, Diamant Thaçi, Aileen L Pangan, H Chih-Ho Hong, Kim A Papp, Kristian Reich, Lisa A Beck, Mohamed-Eslam F Mohamed, Ahmed A Othman, Jaclyn K Anderson,[...]. J Allergy Clin Immunol 2020
138
12

Baricitinib versus Placebo or Adalimumab in Rheumatoid Arthritis.
Peter C Taylor, Edward C Keystone, Désirée van der Heijde, Michael E Weinblatt, Liliana Del Carmen Morales, Jaime Reyes Gonzaga, Sergey Yakushin, Taeko Ishii, Kahaku Emoto, Scott Beattie,[...]. N Engl J Med 2017
417
12

The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis.
Douglas J Veale, Dennis McGonagle, Iain B McInnes, James G Krueger, Christopher T Ritchlin, Dirk Elewaut, Keith S Kanik, Thijs Hendrikx, Gabriel Berstein, Jennifer Hodge,[...]. Rheumatology (Oxford) 2019
44
15

Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial.
Christopher T Ritchlin, Arthur Kavanaugh, Joseph F Merola, Georg Schett, Jose U Scher, Richard B Warren, Alice B Gottlieb, Deepak Assudani, Kathy Bedford-Rice, Jason Coarse,[...]. Lancet 2020
70
12

Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial.
Iain B McInnes, Frank Behrens, Philip J Mease, Arthur Kavanaugh, Christopher Ritchlin, Peter Nash, Jordi Gratacós Masmitja, Philippe Goupille, Tatiana Korotaeva, Alice B Gottlieb,[...]. Lancet 2020
88
12

Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials.
Philip J Mease, Philip S Helliwell, Kasper Fjellhaugen Hjuler, Kyle Raymond, Iain McInnes. Ann Rheum Dis 2021
34
20

Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial.
Iain B McInnes, Arthur Kavanaugh, Alice B Gottlieb, Lluís Puig, Proton Rahman, Christopher Ritchlin, Carrie Brodmerkel, Shu Li, Yuhua Wang, Alan M Mendelsohn,[...]. Lancet 2013
525
12

Clinical significance of Janus Kinase inhibitor selectivity.
Ernest H Choy. Rheumatology (Oxford) 2019
91
12

Efficacy and safety of abatacept, a T-cell modulator, in a randomised, double-blind, placebo-controlled, phase III study in psoriatic arthritis.
Philip J Mease, Alice B Gottlieb, Désirée van der Heijde, Oliver FitzGerald, Alyssa Johnsen, Marleen Nys, Subhashis Banerjee, Dafna D Gladman. Ann Rheum Dis 2017
121
12

Upadacitinib in Patients with Psoriatic Arthritis and Inadequate Response to Biologics: 56-Week Data from the Randomized Controlled Phase 3 SELECT-PsA 2 Study.
Philip J Mease, Apinya Lertratanakul, Kim A Papp, Filip E van den Bosch, Shigeyoshi Tsuji, Eva Dokoupilova, Mauro W Keiserman, Xianwei Bu, Liang Chen, Reva M McCaskill,[...]. Rheumatol Ther 2021
13
53

2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis.
Désirée van der Heijde, Sofia Ramiro, Robert Landewé, Xenofon Baraliakos, Filip Van den Bosch, Alexandre Sepriano, Andrea Regel, Adrian Ciurea, Hanne Dagfinrud, Maxime Dougados,[...]. Ann Rheum Dis 2017
821
10

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.
Peter Nash, Andreas Kerschbaumer, Thomas Dörner, Maxime Dougados, Roy M Fleischmann, Klaus Geissler, Iain McInnes, Janet E Pope, Désirée van der Heijde, Michaela Stoffer-Marx,[...]. Ann Rheum Dis 2021
75
10


Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study.
Jürgen Wollenhaupt, Eun-Bong Lee, Jeffrey R Curtis, Joel Silverfield, Ketti Terry, Koshika Soma, Chris Mojcik, Ryan DeMasi, Sander Strengholt, Kenneth Kwok,[...]. Arthritis Res Ther 2019
148
10

Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials.
K A Papp, M A Menter, M Abe, B Elewski, S R Feldman, A B Gottlieb, R Langley, T Luger, D Thaci, M Buonanno,[...]. Br J Dermatol 2015
192
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.